LGVN News and Press, Longeveron Inc. From 05/13/24

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting changes on its board of directors. The following transitions on the board have been announced: Richard Kender, retired SVP of bu...

2024-05-10 16:15:05 ET More on Longeveron Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript Longeveron stock rallies 85% on Alzheimer's presentation (update) Longeveron stock rallies 75% amid public offering, business update Seeking Alpha’s Quant...

Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board Dr. Roger Hajjar, former head of R&D at Ring Therapeutics, has been nominated as a candidate for the Board, subject to election at the Compan...

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, will be releasing its fi...

MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. fina...

2024-04-30 11:18:34 ET More on Longeveron Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript Longeveron stock rallies 85% on Alzheimer's presentation (update) Longeveron stock rallies 75% amid public offering, business update Seeking Alpha’s Quant...

Longeveron (NASDAQ: LGVN) , a clinical-stage, biotechnology company developing regenerative medicines, is one of 96 companies slated to participate at the Planet MicroCap Showcase: VEGAS. The three-day event begins in Las Vegas tomorrow and runs through May 2, 2024. The event kicks off with ...

Longeveron (NASDAQ: LGVN) , a clinical-stage, biotechnology company developing regenerative medicines, will be presenting at next month’s Planet MicroCap Showcase. The conference is slated for May 1–2, 2024, in Las Vegas. According to the announcement, Longeveron’s presentati...

MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024. Details for the Company’s pres...

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has closed on its warran...